By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.